[
  {
    "ts": null,
    "headline": "Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment",
    "summary": "Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial promise to their oncology pipeline. Over the last quarter, Merck's shares increased by 4.44%, aligning with the broader market's upward trend, exemplified by the S&P 500 and Nasdaq Composite hitting all-time highs. While the company's advancements in KEYTRUDA applications and Health Canada's...",
    "url": "https://finnhub.io/api/news?id=c350907c92f39c069444bbe3c571d09817d8b1739aec812ea3e1f39793d3e19b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755020506,
      "headline": "Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment",
      "id": 136320607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial promise to their oncology pipeline. Over the last quarter, Merck's shares increased by 4.44%, aligning with the broader market's upward trend, exemplified by the S&P 500 and Nasdaq Composite hitting all-time highs. While the company's advancements in KEYTRUDA applications and Health Canada's...",
      "url": "https://finnhub.io/api/news?id=c350907c92f39c069444bbe3c571d09817d8b1739aec812ea3e1f39793d3e19b"
    }
  },
  {
    "ts": null,
    "headline": "Tesla's Stock Should Be 10 Times Cheaper (Rating Downgrade)",
    "summary": "Discover why experts argue Tesla, Inc.'s stock is overvalued, with concerns over stagnant sales, EPS, and other doubts. Click for this TSLA update.",
    "url": "https://finnhub.io/api/news?id=50f29864d66d757a87f39788322410f093ce7e142ab736e780d803283922016c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755016371,
      "headline": "Tesla's Stock Should Be 10 Times Cheaper (Rating Downgrade)",
      "id": 136322645,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1500886695/image_1500886695.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why experts argue Tesla, Inc.'s stock is overvalued, with concerns over stagnant sales, EPS, and other doubts. Click for this TSLA update.",
      "url": "https://finnhub.io/api/news?id=50f29864d66d757a87f39788322410f093ce7e142ab736e780d803283922016c"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics: Maintaining A Small Holding",
    "summary": "MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026. Click here to read why MLTX is a Hold.",
    "url": "https://finnhub.io/api/news?id=a0acb209d90dc26c4ce31ed5581f375bd750bb4043c57820c4b6e45b5b81061b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013945,
      "headline": "MoonLake Immunotherapeutics: Maintaining A Small Holding",
      "id": 136322308,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026. Click here to read why MLTX is a Hold.",
      "url": "https://finnhub.io/api/news?id=a0acb209d90dc26c4ce31ed5581f375bd750bb4043c57820c4b6e45b5b81061b"
    }
  },
  {
    "ts": null,
    "headline": "SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus",
    "summary": "Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.",
    "url": "https://finnhub.io/api/news?id=16584c7e63fc97a940909a82e17bc930b623d0b60616a2651204bdd401d7650f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013380,
      "headline": "SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus",
      "id": 136320222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.",
      "url": "https://finnhub.io/api/news?id=16584c7e63fc97a940909a82e17bc930b623d0b60616a2651204bdd401d7650f"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients",
    "summary": "On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the study’s primary endpoint",
    "url": "https://finnhub.io/api/news?id=c726f113507eda77bf53434a0a9a19d38c4f234b54e5296b1b85e44c1d6751d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755010019,
      "headline": "Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients",
      "id": 136320224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the study’s primary endpoint",
      "url": "https://finnhub.io/api/news?id=c726f113507eda77bf53434a0a9a19d38c4f234b54e5296b1b85e44c1d6751d4"
    }
  },
  {
    "ts": null,
    "headline": "We Think Merck's (NYSE:MRK) Profit Is Only A Baseline For What They Can Achieve",
    "summary": "Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice. Our...",
    "url": "https://finnhub.io/api/news?id=65b6030e871dee913b3b3b945e8e5c0f043eead04cc5ed49502eb8e1543cc769",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755002986,
      "headline": "We Think Merck's (NYSE:MRK) Profit Is Only A Baseline For What They Can Achieve",
      "id": 136320611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice. Our...",
      "url": "https://finnhub.io/api/news?id=65b6030e871dee913b3b3b945e8e5c0f043eead04cc5ed49502eb8e1543cc769"
    }
  },
  {
    "ts": null,
    "headline": "10 Undervalued Dividend Growth Stocks: August 2025",
    "summary": "Discover the top 10 undervalued dividend growth stocks with a 5% yield-on-cost.",
    "url": "https://finnhub.io/api/news?id=a89626b3dd9319096d1f1ad3e5668759981b8186208e985a87fb90110d4d2fe3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754995511,
      "headline": "10 Undervalued Dividend Growth Stocks: August 2025",
      "id": 136318209,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/614833538/image_614833538.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover the top 10 undervalued dividend growth stocks with a 5% yield-on-cost.",
      "url": "https://finnhub.io/api/news?id=a89626b3dd9319096d1f1ad3e5668759981b8186208e985a87fb90110d4d2fe3"
    }
  },
  {
    "ts": null,
    "headline": "US Assisted Reproductive Technology Market Forecast and Company Analysis Report 2025-2033 | Cosmos Biomedical, Microm, CooperSurgical, FUJIFILM Irvine Scientific, Cryolab, Vitrolife, Merck, Ferring",
    "summary": "The United States Assisted Reproductive Technology (ART) Market is projected to grow from US$ 6.01 billion in 2024 to US$ 9.31 billion by 2033, with a CAGR of 4.98% from 2025. Key drivers include rising infertility rates, technological advancements, increased acceptance of fertility treatments, and enhanced insurance and genetic testing. The market segments into technologies like IVF, AI-IUI, and FET, catering to hospitals and fertility clinics. Leading companies like CooperSurgical and Vitrolif",
    "url": "https://finnhub.io/api/news?id=0f9dca7bd82b38927b1e8532b7e5e48eda88f65dd8116605f12681c9dd63adf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754992560,
      "headline": "US Assisted Reproductive Technology Market Forecast and Company Analysis Report 2025-2033 | Cosmos Biomedical, Microm, CooperSurgical, FUJIFILM Irvine Scientific, Cryolab, Vitrolife, Merck, Ferring",
      "id": 136316104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The United States Assisted Reproductive Technology (ART) Market is projected to grow from US$ 6.01 billion in 2024 to US$ 9.31 billion by 2033, with a CAGR of 4.98% from 2025. Key drivers include rising infertility rates, technological advancements, increased acceptance of fertility treatments, and enhanced insurance and genetic testing. The market segments into technologies like IVF, AI-IUI, and FET, catering to hospitals and fertility clinics. Leading companies like CooperSurgical and Vitrolif",
      "url": "https://finnhub.io/api/news?id=0f9dca7bd82b38927b1e8532b7e5e48eda88f65dd8116605f12681c9dd63adf7"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., August 12, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically mea",
    "url": "https://finnhub.io/api/news?id=7dc2ddfe18f37322e42388095fb2c5b0bd68d43464fdf2d254f8675cf79db216",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754991180,
      "headline": "KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
      "id": 136316105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., August 12, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically mea",
      "url": "https://finnhub.io/api/news?id=7dc2ddfe18f37322e42388095fb2c5b0bd68d43464fdf2d254f8675cf79db216"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
    "summary": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
    "url": "https://finnhub.io/api/news?id=dc65ae83c1a5efb04c24fb802e3932778cb143c9644f51a4bff8f7c3ab0d7c0f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754984160,
      "headline": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
      "id": 136331957,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
      "url": "https://finnhub.io/api/news?id=dc65ae83c1a5efb04c24fb802e3932778cb143c9644f51a4bff8f7c3ab0d7c0f"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons We’re Fans of Merck (MRK)",
    "summary": "Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=b0a8d95153dccf67b5c57d26d874afae3061922bd29fbb199404df6f1f24cf0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754971287,
      "headline": "3 Reasons We’re Fans of Merck (MRK)",
      "id": 136316106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=b0a8d95153dccf67b5c57d26d874afae3061922bd29fbb199404df6f1f24cf0d"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Begin Phase 3 Trials for Investigational Monthly HIV Prevention Pill",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has announced the start of two Phase 3 trials to evaluate MK-8527, an experimental once-monthly oral PrEP therapy: EXPrESSIVE-10 and EXPrESSIVE-11. The EXPrESSIVE-11 trial, which is enrolling people in 16 countries worldwide, […]",
    "url": "https://finnhub.io/api/news?id=2f445bb82d438eca49bb42ec1c09356786dc415c71495f551eef49427d808d27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754957963,
      "headline": "Merck to Begin Phase 3 Trials for Investigational Monthly HIV Prevention Pill",
      "id": 136316107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has announced the start of two Phase 3 trials to evaluate MK-8527, an experimental once-monthly oral PrEP therapy: EXPrESSIVE-10 and EXPrESSIVE-11. The EXPrESSIVE-11 trial, which is enrolling people in 16 countries worldwide, […]",
      "url": "https://finnhub.io/api/news?id=2f445bb82d438eca49bb42ec1c09356786dc415c71495f551eef49427d808d27"
    }
  }
]